Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylenediamine SCHEMBL28206380 | 0.92 | RAB9A (0.51) | RAB9AMEN1KMT2ACASP6ALDH1A1 | |
| Quinoline SCHEMBL28205874 | 0.89 | HSP90AA1 (0.54) | RAB9AMEN1KMT2ACASP6ALDH1A1 | |
| SCHEMBL1682777 | 0.80 | RAB9A (0.55) | RAB9AMEN1KMT2ACASP6ALDH1A1 | |
| SCHEMBL9120430 | 0.80 | RAB9A (0.55) | RAB9AMEN1KMT2ACASP6ALDH1A1 | |
| Acridine SCHEMBL27545385 | 0.79 | RAB9A (0.63) | RAB9AMEN1KMT2AALDH1A1HTT | |
| SCHEMBL2425847 | 0.79 | HTT (0.58) | RAB9AMEN1KMT2ACASP6ALDH1A1 | |
| SCHEMBL14661558 | 0.79 | RAB9A (0.54) | RAB9AMEN1KMT2ACASP6ALDH1A1 | |
| SCHEMBL28818163 | 0.79 | RAB9A (0.54) | RAB9AMEN1KMT2ACASP6ALDH1A1 | |
| SCHEMBL11108095 | 0.79 | RAB9A (0.54) | RAB9AMEN1KMT2ACASP6ALDH1A1 | |
| SCHEMBL2011678 | 0.79 | RAB9A (0.54) | RAB9AMEN1KMT2ACASP6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109310757-A | Nitroxoline and its analog and the combined use of chemotherapy and immunotherapy in cancer treatment | 爱西里斯药物技术有限公司 | 2019-02-05 | — | — | CN | claimed |
| JP-2225486-A | — | — | None | — | — | JP | disclosed |
| CN-112402388-A | Oral solid preparation for treating bladder cancer and preparation method thereof | 江苏亚虹医药科技股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-109310757-A | Nitroxoline and its analog and the combined use of chemotherapy and immunotherapy in cancer treatment | 爱西里斯药物技术有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-105228984-B | Base addition salts of nitroxoline and uses thereof | 爱西里斯药物技术有限公司 | 2018-03-23 | — | — | CN | disclosed |
| CN-104010525-B | Cyclohexanol derivative as antibacterial anti-microbial active matter purposes | 默克专利股份有限公司 | 2017-08-25 | — | — | CN | disclosed |
| CN-105228984-A | Base addition salts of nitroxoline and uses thereof | ASIERIS PHARMACEUTICAL TECHNOLOGIES CO LTD | 2016-01-06 | — | — | CN | disclosed |
| US-9062046-B2 | Substituted imidazoquinoline derivatives as kinase inhibitors | Piramal Enterprises Limited (IN) | 2015-06-23 | — | — | US | disclosed |
| WO-2014141118-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AND USES THEREOF | Piramal Enterprises Limited (IN) | 2014-09-18 | — | — | WO | disclosed |
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | PIRAMAL ENTERPRISES LIMITED` (IN) | 2013-11-21 | — | — | US | disclosed |
| EP-2648733-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | Piramal Enterprises Limited (IN) | 2013-10-16 | — | — | EP | disclosed |
| EP-2593450-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-09 | — | — | US | disclosed |
| WO-2012077031-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012007926-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-01-19 | — | — | WO | disclosed |
| EP-0317188-B1 | Heteroaromatic enamide derivatives and their use as pesticides | ROUSSEL UCLAF (FR) | 1995-09-27 | — | — | EP | disclosed |
| US-5114940-A | Insecticides or anthelmintics from fused ring heterocycles containing amides or thioamides | ROUSSEL-UCLAF (FR) | 1992-05-19 | — | — | US | disclosed |
| JP-H02225486-A | SPIROXAZINE-BASED COMPOUND AND PHOTOSENSITIVE MATERIAL USING THE SAME COMPOUND | MITSUBISHI KASEI CORP | 1990-09-07 | — | — | JP | disclosed |
| EP-0317188-A2 | Heteroaromatic enamide derivatives and their use as pesticides | ROUSSEL UCLAF (FR) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK4, MAP3K1 | RAB9A 1389/4885MEN1 2898/4885KMT2A 787/4885 |
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | FLT4, CDK4, CDK2 | RAB9A 2007/4885MEN1 3337/4885KMT2A 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.